Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JS7 plasmid DNA and MVA62B vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| JS7 plasmid DNA and MVA62B vaccine | BIOLOGICAL | JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25) |
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
The JS7 plasmid DNA and MVA62B vaccine is an investigational HIV-1 vaccine regimen developed by GeoVax Labs, Inc. It uses a plasmid DNA prime followed by an MVA boost to deliver HIV immunogens. It is being studied in adults infected with HIV-1 who are receiving antiretroviral therapy.
It is being studied as a therapeutic vaccine for HIV-1 infection in adults already on antiretroviral therapy. The goal is to stimulate immune responses against HIV-1. It is investigational and has not been approved for any indication.
GeoVax Labs, Inc. is developing the JS7 plasmid DNA and MVA62B vaccine. GeoVax Labs trades on the Nasdaq under the ticker GOVX. The company is the sponsor of the clinical program for this HIV-1 vaccine regimen.
The JS7 plasmid DNA and MVA62B vaccine is in Phase 1 development. Its only recorded trial, NCT01378156, is a completed Phase 1 study. The vaccine is investigational and has not been approved by the FDA or any other regulator.
The JS7 plasmid DNA and MVA62B vaccine has been studied in one Phase 1 trial, NCT01378156, titled A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART. That trial is completed and enrolled 9 participants.
No. The Phase 1 trial NCT01378156 was an uncontrolled study, not randomized and not double blinded. It enrolled 9 participants with HIV-1 infection who were on antiretroviral therapy, and it is listed as completed.